The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era

BACKGROUND: The ALTER0203 clinical trial showed that anlotinib, a multitargeted tyrosine kinase inhibitor, had antitumor effects on advanced soft tissue sarcoma (STS) after the failure of standard chemotherapy. We aimed to evaluate the real‐world efficacy and explore prognostic factors and treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ren‐Shu, Liu, Jie, Deng, Yao‐Tiao, Wu, Xin, Jiang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160813/
https://www.ncbi.nlm.nih.gov/pubmed/35191609
http://dx.doi.org/10.1002/cam4.4613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160813/
https://www.ncbi.nlm.nih.gov/pubmed/35191609
http://dx.doi.org/10.1002/cam4.4613

Ejemplares similares